Mundi Pharma signs co-sales agreement of ADHD therapy ‘Bisphentin’
Mundi Pharma(CEO Myung-Sae Lee) signed a co-sales agreement of ‘Bisphentin Controlled-Release Cap(generic name: methylphenidate hydrochloride),’ an attention-deficit/hyperactivity disorder(ADHD) therapy, with Korea Pharma(CEO/Chairman Jae-Don Park).
Under the agreement, Korea Pharma will exclusi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
